Roche's Drug and Diagnostics Arm Supports a Wide Moat
Following the annual meeting of the American Society of Clinical Oncology, we're maintaining our Roche fair value estimate of $42/CHF 343 per share, and shares traded at a more than 20% discount to our valuation at Monday's close. Data at the meeting supporting our bullish view on several of Roche's drugs, including Venclexta in CLL and Tecentriq in lung cancer patients with liver metastases, triple-negative breast cancer, and adjuvant indications. We think Roche is also well positioned to weath...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.